Estrogen Replacement and Ovarian Cancer.


Estrogen Replacement and Ovarian Cancer

Estrogen replacement therapy and fatal ovarian cancer.

Rodriguez C Calle EE Coates RJ Miracle-McMahill HL Thun MJ Heath CW Jr. Am J Epidemiol (1995 May 1) 141(9):828-35

The authors examined the relation between use of estrogen replacement therapy and ovarian cancer mortality in a large prospective mortality study of 240,073 peri- and post-menopausal women, none of whom had a prior history of cancer, hysterectomy or ovarian surgery at enrollment in 1982. During 7 years of follow-up, 436 deaths from ovarian cancer occurred. Cox proportional hazard regression was used to adjust for other risk factors. Use of estrogen replacement therapy was associated with a rate ratio for fatal ovarian cancer of 1.15 (95% confidence interval (CI) 0.94-1.42). The mortality rate ratio increased with duration of use prior to entry to this study to 1.40 (95 CI% 0.92-2.11)with 6-10 years of use and 1.71 (95% CI 1.06- 2.77) with > or = 11 years of use. The increase in mortality associated with > or = 6 years of use was observed in both current users (rate ratio (RR) = 1.72, 95% CI 1.01-2.90) and former users at study entry (RR = 1.48, 95% CI 0.99-2.22), relative to never users. Risk associated with use was not modified by any of the other risk factors. These data suggest that long-term use of estrogen replacement therapy may increase the risk of fatal ovarian cancer.

Life Extension Foundation.

Share this with your friends